Payment overview · 2025
General Payments
$499.87
21 reported records · 10 companies
Healthcare provider profile · identity verified
Maqsood Javed, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1073568713
Verified facts
What the public records show
CMS Open Payments records show Maqsood Javed, M.D. received $499.87 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 162 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $144.61 | 28.9% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $93.66 | 18.7% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $72.04 | 14.4% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.44 | 6.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.88 | 6.6% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.27 | 6.5% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $29.21 | 5.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.39 | 4.9% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $20.42 | 4.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.95 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $467.60 | 20 |
| Education | $32.27 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $102.41 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $93.66 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $84.54 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $72.04 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $42.20 | 2 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $34.44 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.88 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.27 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $32.26 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.21 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 46 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 162 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
36 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
23 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
162 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 719 | 244 |
| Levothyroxine Sodium | Levothyroxine Sodium | 385 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 354 | 121 |
| Losartan Potassium | Losartan Potassium | 310 | 105 |
| Metoprolol Succinate | Metoprolol Succinate | 298 | 91 |
| Lisinopril | Lisinopril | 242 | 80 |
| Gabapentin | Gabapentin | 240 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 184 | 69 |
| Metformin Hcl | Metformin Hcl | 177 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 164 | 57 |
| Ozempic | Semaglutide | 162 | 35 |
| Omeprazole | Omeprazole | 161 | 68 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 141 | 49 |
| Glimepiride | Glimepiride | 137 | 43 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 124 | 38 |
| Trazodone Hcl | Trazodone Hcl | 121 | 44 |
| Mounjaro | Tirzepatide | 120 | 29 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 50 |
| Sertraline Hcl | Sertraline Hcl | 117 | 35 |
| Furosemide | Furosemide | 116 | 40 |
| Simvastatin | Simvastatin | 113 | 36 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 63 |
| Azithromycin | Azithromycin | 107 | 95 |
| Hydralazine Hcl | Hydralazine Hcl | 106 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 38 |
| Tramadol Hcl | Tramadol Hcl | 102 | 51 |
| Ondansetron Hcl | Ondansetron Hcl | 92 | 46 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 91 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 88 | 35 |
| Celecoxib | Celecoxib | 88 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 88 | 30 |
| Montelukast Sodium | Montelukast Sodium | 86 | 28 |
| Carvedilol | Carvedilol | 82 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 27 |
| Azelastine Hcl | Azelastine Hcl | 77 | 48 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 74 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 73 | 39 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 18 |
| Meloxicam | Meloxicam | 72 | 21 |
| Buspirone Hcl | Buspirone Hcl | 69 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 68 | 40 |
| Potassium Chloride | Potassium Chloride | 67 | 21 |
| Alendronate Sodium | Alendronate Sodium | 65 | 19 |
| Dexamethasone | Dexamethasone | 65 | 60 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 64 | 55 |
| Eliquis | Apixaban | 62 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 59 | 17 |
| Allopurinol | Allopurinol | 55 | 16 |
| Glipizide | Glipizide | 54 | 16 |
| Metformin Hcl Er | Metformin Hcl | 54 | 21 |
| Mupirocin | Mupirocin | 54 | 39 |
| Valsartan | Valsartan | 52 | 18 |
| Atenolol | Atenolol | 49 | 16 |
| Clonazepam | Clonazepam | 49 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 49 | 15 |
| Fenofibrate | Fenofibrate | 47 | 14 |
| Levofloxacin | Levofloxacin | 47 | 41 |
| Meclizine Hcl | Meclizine Hcl | 47 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 30 |
| Clonidine Hcl | Clonidine Hcl | 46 | 18 |
| Farxiga | Dapagliflozin Propanediol | 46 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 46 | suppressed |
| Spironolactone | Spironolactone | 45 | 17 |
| Famotidine | Famotidine | 44 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Linzess | Linaclotide | 38 | 15 |
| Ramipril | Ramipril | 38 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 38 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | 11 |
| Tradjenta | Linagliptin | 36 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Sucralfate | Sucralfate | 33 | 14 |
| Fenofibrate | Fenofibrate Nanocrystallized | 32 | 11 |
| Glipizide Er | Glipizide | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Finasteride | Finasteride | 31 | suppressed |
| Folic Acid | Folic Acid | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Ezetimibe | Ezetimibe | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | 12 |
| Methylprednisolone | Methylprednisolone | 28 | 24 |
| Mirtazapine | Mirtazapine | 28 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | 11 |
| Lorazepam | Lorazepam | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 23 | suppressed |
| Jardiance | Empagliflozin | 23 | 11 |
| Naproxen | Naproxen | 23 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | 18 |
| Prednisone | Prednisone | 22 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Lactulose | Lactulose | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Pregabalin | Pregabalin | 18 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 17 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | 11 |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $499.87 · 21 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, FARXIGA, Korlym, OFEV, OTEZLA, Ozempic, REPATHA, REXULTI, TRELEGY ELLIPTA, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error